For Bristol, Plavix Ruling Bodes Well In Patent Trial

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

The New York Sun

Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY) now have the upper hand in an upcoming patent trial over their blockbuster heart drug Plavix, if Thursday’s court injunction in the case is any indication.

The main reason: In granting an injunction halting sales of a generic version of Plavix, U.S. Judge Sidney Stein in New York concluded that Bristol-Myers and Sanofi-Aventis were likely to prevail over generic marketer Apotex Inc. at a trial scheduled to begin in January. Stein is the judge who will deliver the verdict in the non-jury trial.

Enter your email to read this article.

Get 2 free articles when you subscribe.

or
Have an account? This is also a sign-in form.
By continuing you agree to our Privacy Policy and Terms of Service.
Advertisement
The New York Sun

© 2025 The New York Sun Company, LLC. All rights reserved.

Use of this site constitutes acceptance of our Terms of Use and Privacy Policy. The material on this site is protected by copyright law and may not be reproduced, distributed, transmitted, cached or otherwise used.

The New York Sun

Sign in or  Create a free account

or
By continuing you agree to our Privacy Policy and Terms of Use